CONTINUE TO SITE
OR WAIT null SECS
© 2021 MJH Life Sciences™ and Modern Retina. All rights reserved.
AAO 2020: Alimera highlights NEW DAY Study for sustained-release intravitreal implant
November 15, 2020
OT Staff Reports
OT Staff Reports
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.
Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.